The use of a combination treatment of ATRA and inhibitor of ERK could potentially be used as a treatment to reduce proliferation, promote apoptosis, and prevent the process of cell migration induced by ATRA in patients with lung cancer. This evidence concerns the gene MAPK1 and lung carcinoma.